MedTrace Logo

Treatment of Severe Peanut Allergy With Xolair (Omalizumab) and Oral Immunotherapy

NCT02402231 · Status: UNKNOWN · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 23

Last updated 2018-08-24

No results posted yet for this study

Summary

Severe peanut allergy is different from other allergic reactions because it can lead to fatal reactions and is an invisible disability. There is no cure today. The purpose of this study is to treat children and adolescents with severe peanut allergy with oral immunotherapy with peanuts under the protection of anti-IgE (immunoglobulin E) antibodies (omalizumab), and thereby inducing tolerance to peanuts. The treatment will be monitored by basophil cell stimulation (CD-sens).

Conditions

Interventions

DRUG

Omalizumab

Omalizumab is the treatment during oral immunotherapy with peanuts as protection

Sponsors & Collaborators

  • Caroline Nilsson

    lead OTHER

Principal Investigators

  • Caroline Nilsson, MD, PhD · Dept of Clinical Science and Education, Karolinska Institutet

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
12 Years
Max Age
22 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2013-10-31
Primary Completion
2020-10-31
Completion
2020-10-31

Countries

  • Sweden

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02402231 on ClinicalTrials.gov